Oncology

AstraZeneca announced that its immuno-oncology drug durvalumab, in combination with tremelimumab, failed to meet a progression-free survival endpoint in the MYSTIC trial in patients with metastatic non-small cell lung cancer (NSCLC).

A new study has analyzed data from randomized controlled trials in oncology that used surrogate endpoints and measured their relation with treatment effectiveness and patient survival in the real world.

Study used gene biomarker to identify which patients with colon cancer would not benefit from chemotherapy.

During a panel hosted by the National Cancer Institute (NCI), patient advocates and survivorship experts discussed the strides made in the field of cancer survivorship research.

Researchers have identified a cellular signaling pathway that when activated by mutations may prevent immune cells from infiltrating bladder tumors, thus making the cancer resistant to immune checkpoint inhibitors.

This study investigates the cost-effectiveness of a community-based patient navigation program to improve cervical cancer screening.

The Women’s Health Initiative Dietary Modification Trial examined the long-term influence of low-fat eating patterns on the breast cancer mortality rate.

Patient refusal, symptom burden, and diagnostic disparities were identified as some of the most common barriers encountered when recruiting patients with advanced cancer for palliative treatment in the emergency department (ED).

The Journal of Clinical Investigation Insight recently published a study that analyzed 112 different melanoma tumors in attempt to correlate partially exhausted cytotoxic lymphocytes (peCTLs) and regulatory T lymphocyte (Treg) levels with response to combination immunotherapy.

Being overweight or obese as a teenager raises the risk of developing colon cancer later in life, a new study in the journal CANCER has found.

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine tumors to analyze their resource utilization.

In a study presented at the 2017 American Society of Clinical Oncology Annual Metting, researchers from the Brazilian Cancer Foundation and the Brazilian National Cancer Institute evaluated the cost-effectiveness of a unique exam using next-generation sequencing versus other routine tests.

Including adjuvant chemotherapy in the postsurgical treatment plan in patients with non—small cell lung cancer (NSCLC) improves survival and is cost-effective compared with surgical resection alone, according to analysis results presented at the 2017 American Society of Clinical Oncology Annual Meeting.

CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2—positive early breast cancer, according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Research presented at the 2017 American Society of Clinical Oncology Annual Meeting showed that SB3, a proposed biosimilar to trastuzumab, has comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product based on the breast pathological complete response.

After switching studies, research in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar, according to results presented at the 2017 Annual Meeting of the American Society of Clinical Oncology.

This week, the top managed care stories included more twists in Senate Republicans' efforts to repeal the Affordable Care Act; a Medicare fraud sweep targeted opioid distribution; and the CDC reported 30 million Americans now have diabetes.

Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.

In a webinar hosted by Carevive, researcher Ethan Basch, MD, MSc, discussed the findings of his recent study linking electronic patient-reported outcomes (PROs) to better survival outcomes for patients with cancer.

A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology led by Katherine Van Loon, MD, MPH, examined retrospective surveillance data in 3 cancers: non—small cell lung cancer, head and neck cancer, and colorectal cancer.

At the 2017 American Society of Clinical Oncology Annual Meeting, oncologists heard from fellow experts on the best way to navigate the daunting challenge of payment reform.

A kickoff session on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago turned in to a lively discussion on ensuring that the data used to inform patient care and create healthcare policies hold value, which could entail foraging real-world data captured in health records.

According to outcome results presented at a plenary session at the 2017 American Society of Clinical Oncology Annual Meeting, patients receiving routine outpatient chemotherapy for metastatic solid tumors who self-reported 12 common symptoms via tablet computers experienced an overall survival benefit over those who received usual care.

A poster session at the 2017 American Society of Clinical Oncology Annual Meeting presented the trial details of IRONCLAD, a randomized phase 3 study of ibrutinib versus no consolidation following autologous hematopoietic stem cell transplantation for activated-B-cell subtype relapsed diffuse large B-cell lymphoma.